Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | R289 |
Synonyms | |
Therapy Description |
R289 is a prodrug of R835, an inhibitor of IRAK1 and IRAK4, which potentially leads to decreased production of proinflammatory cytokines and immune cell-mediated cell killing (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
R289 | R906289 monosodium | IRAK1/4 Inhibitor 2 | R289 is a prodrug of R835, an inhibitor of IRAK1 and IRAK4, which potentially leads to decreased production of proinflammatory cytokines and immune cell-mediated cell killing (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05308264 | Phase Ib/II | R289 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Recruiting | USA | 0 |